7:30 pm
Welcome Reception

THURSDAY – FEBRUARY 14

7:15 am  – Breakfast Symposium
Emerging Applications for Cellular Therapy
(Supported by Miltenyi Biotec GmbH, Inc.)

8:30 am
Stem Cell Trafficking and Kinetics 
   ■ Stem Cells Trafficking to and Interactions with the Niche
          David Scadden, MD
   ■ Mesenchymal Stem Cells and Immune Function
          Willem Fibbe, MD, PhD
   ■ Quantitating Stem Cells and Their Divisive Capacity
          Janis Abkowitz, MD

10:30 am
Memory T Cells 
   ■ T Cells in GVHD
          Nelson Chao, MD 
   ■ Memory T Cells in GVHD
          Warren D. Shlomchik, MD
   ■ Functional Differences of Memory T Cells
          Benny J. Chen, MD

10:30 am
Endothelial Biology and Transplant-Related Complications
   ■ Contribution of Endothelial Activation and Injury To End-Organ Toxicity Following
      Allogeneic Hematopoietic Stem Cell Transplantation
          Kenneth R. Cooke, MD
   ■ Endothelial Cells:  Potential Novel Targets for GVHD
          Anne Janin, MD, PhD
   ■ Overview, Diagnosis and Treatment of Thrombotic Microangiopathy after Allogeneic
      Hematopoietic Stem Cell Transplantation
          Vincent T. Ho, MD 

10:30 am

International Session
Organized by the Worldwide Group for Blood and Marrow Transplantation
Chairs:  Dietger Niederwieser, MD, and Mary Horowitz, MD, MS

   ■ Radiation Accident Planning
          Theodor M. Fliedner, MD

   ■ RITN:  A U.S. Initiative for Nuclear Preparedness
          Dennis L. Confer, MD 
   ■ The Challenge of Biosimilars
          Dietger Niederwieser, MD
   ■ Classification of HLA-Matching:  A Proposal for Retrospective Analyses
          Daniel J. Weisdorf, MD 

10:30 am
Immunotherapy for Pediatric Cancer
Laurence J.N. Cooper, MD, Chair
   ■ Cell Therapies in High-Risk Pediatric Malignancies
         Stephen A. Grupp, MD, PhD
   ■ Harnessing the (Natural) Killer during Transplantation
         Michael R. Verneris, MD
   ■ Incorporation of Therapeutic Monoclonal Antibodies into Childhood Cancer Trials
         Paul M. Sondel, MD, PhD

12:15 pm  – Luncheon Symposium
Reduced-Intensity Conditioning Regimens:  Is There an Ideal?
(Supported by PDL BioPharma, Inc.)

12:15 pm
Pediatric International Session and Luncheon
Carmem Bonfim, MD, and Richard Kadota, MD, Co-Chairs
   ■ Cord Blood Transplantation in Japan
         Shunichi Kato, MD, PhD
   ■ Hematopoietic Stem Cell Transplantation for Fanconi's Anemia
         Mouhab Ayas, MD 
   ■ Pediatric Transplantation in Eastern Europe
         Giorgio Dini, MD
   ■ Current Status and Future Trends of Stem Cell Transplantation for Thalassemia in Thailand
         Preeda Vanichsetakul, MD

1:30 pm
Alternative Allogeneic Donor Sources for Transplantation for Childhood Diseases 
Mitchell S. Cairo, MD, Chair
   ■ Unrelated Donor Transplants for Pediatric Nonmalignant Disease, including
      Hemoglobinopathies
         Vanderson Rocha, MD, PhD
   ■ Haploidentical Transplants for Childhood Hematologic Malignancies
         Gregory A. Hale, MD
   ■ The Influence of Cell Dose and HLA Match on Unrelated Cord Blood Transplantation
         John E. Wagner, MD 

1:30 pm
Pediatric Perspectives on Immune Reconstitution and Vaccination
   ■ Improved Immune Reconstitution and Low Mortality after Haploidentical Transplantation
      Using Reduced-Intensity Conditioning and CD3/CD19 Depletion
         Rupert Handgretinger, MD
   ■ Immune Reconstitution after Unrelated Cord Blood Transplantation:  The Expected and
      the Unique
         Paul Szabolcs, MD
   ■ Revaccination after Allogeneic Stem Cell Transplantation
         Trudy N. Small, MD

3:15 pm
Hematopoietic Stem Cell Transplantation for Severe Combined Immunodeficiency Diseases
   ■ Issues of Transplantation for SCID
         Morton J. Cowan, MD
   ■ Late Immunological and Clinical Outcome for a Large Cohort of Transplanted SCID Patients
         Bénédicte Neven, MD
   ■ Newborn Screening for SCID
         Jennifer M. Puck, MD
   ■ To Ablate or Not To Ablate: That Is the Question  (Panel Discussion)
         Trudy M. Small, MD; Luigi D. Notarangelo, MD; Naynesh Kamani, MD; Neena Kapoor, MD; 
         and Alexandra H. Filipovich, MD

3:15 pm
Late Effects of Transplantation in Children and Adolescents
   ■ Oral and Dental Late Effects after Pediatric Stem Cell Transplantation
         Göran Dahllöf, DDS, PhD
   ■ The Kidney after Hematopoietic Cell Transplantation
         Sangeeta Hingorani, MD, MPH
   ■ Evaluation for Late Effects after Pediatric Hematopoietic Cell Transplantation
         Jean E. Sanders, MD

4:45 pm
Oral Abstracts

6:15 pm
Poster Session I

7:30 pm  – Dinner Symposium
CMV Disease in Stem Cell Transplantation:  Challenges and Opportunities
(Supported by ViroPharma Incorporated)

FRIDAY – FEBRUARY 15

7:15 am  – Breakfast Symposium
Strategies for the Management of Iron Overload in the Transplant Setting
(Supported by Novartis Pharmaceuticals Corporation.)

8:30 am
Tolerance Induction for Hematopoietic and Solid Organ Graft Acceptance
   ■ Costimulation Blockade and Chimerism Strategies for Organ Transplant Tolerance
          Christian P. Larsen, MD, PhD
   ■ Embryonic Pig Tissues as a Source for Organ Transplantation
          Yair Reisner, PhD
   ■ Regulation of Allogeneic T Cell Responses in BMT
          Bruce R. Blazar, MD

10:30 am
Clinical Strategies to Enhance Post-Transplant Immune Reconstitution

   ■ Notch Signaling in Hematopoiesis:  Implications for Improving Stem Cell Transplantation
          Irwin Bernstein, MD
   ■ Enhancement of Immune Reconstitution Following Myeloablative Chemotherapy by
      Inhibition of Sex Steroid Production
          Richard Boyd, PhD
   ■ Interleukin-7 and Keratinocyte Growth Factor and Lymphoid Precursors for Post-Transplant
      T Cell Reconstitution 

          Marcel R.M. van den Brink, MD, PhD

10:30 am
Controversies in Lymphoma Therapy
   ■ Diffuse Large Cell Lymphoma:  From Gene Expression Profiling to Prediction of Outcome
          Izidore S. Lossos, MD
   ■ Hematopoietic Cell Transplantation for T Cell Non-Hodgkin Lymphoma:  Does it Work?
          Ginna G. Laport, MD
   ■ Mantle Cell Lymphoma in First Remission:  What Next?
          Peter Dreger, MD, PhD

10:30 am
Selecting Donors and Cord Blood Units:  Evidence-Based Decisions (NMDP Session)
   ■ Selecting Optimal Adults Donors
          Stephanie Lee, MD, MPH
   ■ Selecting Optimal Cord Blood Units
          Naynesh Kamani, MD
   ■ Making the Decision – Donor Selection Case Studies
          Dennis Confer, MD

12:15 pm  – Luncheon Symposium
The Hematology Circle:  Stem Cell Transplant in the Continuum of Care for Multiple Myeloma
(Supported by Celgene Corporation)

4:45 pm
Best Abstracts Session

6:30 pm
E. Donnall Thomas Lecture
     The Genetics of Hematopoietic Cell Transplantation
          John A. Hansen, MD 

7:30 pm  – Dinner Symposium
Risky Business:  Invasive Fungal Infections in HSCT
(Supported by Schering-Plough Corporation)

SATURDAY – FEBRUARY 16

7:15 am  – Concurrent Breakfast Symposia

Front-Line Therapy for Multiple Myeloma and Mantle Cell Lymphoma:  The Role of Hematopoietic Cell Transplantation and Proteasome Inhibition Therapies
(Supported by Millennium Pharmaceuticals)

Improving Outcomes in Chronic GVHD Through Immune Regulation

(Supported by THERAKOS, Inc.)

8:30 am
Human Polymorphism and the Outcome of Therapy
   ■ Pharmacogenetics and the Outcome of Therapy for Leukemia
          Stella M. Davies, MD, PhD
   ■ Cytokine Gene Polymorphism and Outcome of Hematopoietic Transplantation
          Anne Dickinson, PhD
   ■ KIR Gene Polymorphism and Therapy of Leukemia
          Jeffrey Miller, MD

10:30 am
Oral Abstracts

12:15 pm  – Luncheon Symposium
Antifungal Prophylaxis Against Mould Infections:  Debating the Pros and Cons
(Supported by Pfizer Inc)

1:30 pm
Medical Directors Conference

Delivery of Quality Care:  Process, Outcomes and Reporting

   ■ The SCTOD – An Early-Phase Progress Report

          Mary Horowitz, MD, MS
   ■ The SCTOD – With Your Help, We Can Get It Right

          Roy B. Jones, MD, PhD
   ■ Process that Supports Good Outcomes – Is Your Quality Plan Ready?

          C. Fred LeMaistre, MD

1:30 pm
Mouse Models of BMT
   ■ The Fundamentals of Mouse BMT Models
          Geoff Hill, MD
   ■ Imaging Graft-versus-Host Reactions in Living Animals
          Robert Negrin, MD
   ■ Mouse Models of GVL:  Promise and Pitfalls
          Pavan Reddy, MD

3:00 pm
Regulatory Affairs Session
   ■ FDA Update

          Celia M. Witten, MD

4:45 pm
T Cell Therapy
   ■ Adoptive Transfer of Virus-Specific T Cells
          Helen Heslop, MD
   ■ Treatment of Hematological Malignancies with Alloreactive T Cells
          J.H. Frederik Falkenburg, MD, PhD
   ■ Anti-Tumor Therapy with T Cells Recognizing Tumor-Associated Self-Antigens
          John Barrett, MD

4:45 pm
Chronic GVHD:  How Can We Release Prometheus?
   Paul J. Martin, MD
   ■ Immunobiology of Chronic GVHD:  Insights from Animal Models
          Takanori Teshima, MD
   ■ Pathophysiology of Fibrosis
          Thomas A. Wynn, PhD
   ■ Treg for Treatment of Chronic GVHD:  Promise or Peril?
           Robert J. Soiffer, MD

4:45 pm
Stem Cells and Regenerative Medicine
   ■ Adult Bone Marrow and Cord Blood-Derived Very Small Embryonic-Like Stem Cells – Our
        Key to Longevity
          Mariusz Ratajczak, MD, PhD
   ■ The Homeostatic Pressure Exerted by Stem Cells in Degenerative or Injured CNS
      Environments
          Evan Snyder, PhD
   ■ The Role of Adult Stem Cells from Bone Marrow and Cord Blood in Regenerative Medicine
           Jan A. Nolta, PhD

6:15 pm 
Poster Session II

7:15 pm
ASBMT President's Dinner 

9:00 pm
BMT Tandem Meetings Gala  
 

SUNDAY – FEBRUARY 17

8:30 am
Transplants for Acute Leukemia
   ■ Pediatric Acute Leukemia
          Stella M. Davies, MD, PhD
  ■ Adult Acute Lymphoblastic Leukemia
          Jacob Rowe, MD
  ■ Adult Acute Myeloid Leukemia
          Frederick R. Appelbaum, MD

10:30 am
Oral Abstracts

12:15 pm 

The Aging Stem Cell and its Niche:  Implications for Stem Cell Function, Transplantation and Transformation
   ■ Aging Stem Cells:  Role of Genetics on Function
          Gary Van Zant, PhD
   ■ Cell Intrinsic and Environmental Alterations Limiting Stem Cell Function During Aging
          Lenhard Rudolph, MD
   ■ Declining Cellular Fitness with Age Promotes the Adaptive Evolution of Cancer
          James DeGregori, PhD

12:15 pm
Graft Failure after Hematopoietic Stem Cell Transplantation
   ■ Graft Failure – An Increasing Problem after Hematopoietic Stem Cell Transplantation
          Olle Ringdén, MD, PhD   

   ■ Overcoming Host-versus-Graft Reactions:  Preclinical Studies and Clinical Translation
          Rainer F. Storb, MD
   ■ Antibody-Mediated Graft Failure after Allogeneic Hematopoietic Stem Cell Transplantation
          Jonas Mattsson, MD

2:00 pm
Adjourn